Ted Walker, MD

Gastroenterology Fellow

Washington University in St. Louis (WU)

We are interested in studying reduced infusion times for Remicade (infliximab) for patient with inflammatory bowel disease (IBD). Recent studies have suggest that short infusion times are safe and cost effective. We would like to evaluate the safety of shorter infusion times, adverse event rates, and cost savings associated with this. In order to better develop our protocol we would like to know how many Remicade infusions are being done in our infusion centers for patient with IBD in the CAM (5th and 10th floor) as well as BJWC and South County.